These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20133082)

  • 1. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
    Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
    Kubicek GJ; Axelrod RS; Machtay M; Ahn PH; Anne PR; Fogh S; Cognetti D; Myers TJ; Curran WJ; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1192-7. PubMed ID: 22245208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
    Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
    Reece DE; Sanchorawala V; Hegenbart U; Merlini G; Palladini G; Fermand JP; Vescio RA; Liu X; Elsayed YA; Cakana A; Comenzo RL;
    Blood; 2009 Aug; 114(8):1489-97. PubMed ID: 19498019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
    Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
    Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
    J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
    Lieu C; Chow L; Pierson AS; Eckhardt SG; O'Bryant CL; Morrow M; Tran ZV; Wright JJ; Gore L
    Invest New Drugs; 2009 Feb; 27(1):53-62. PubMed ID: 18618082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.